A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but the mechanisms underlying their immunosuppressive effects remain unknown. By inducing the down-regulation of mucosal addressin cell adhesion molecule 1 (MAdCAM-1) in the ileum, post-ABX gut recolonization by Enterocloster species drove the emigration of enterotropic α4β7 + CD4 + regulatory T 17 cells into the tumor. These deleterious ABX effects were mimicked by oral gavage of Enterocloster species, by genetic deficiency, or by antibody-mediated neutralization of MAdCAM-1 and its receptor, α4β7 integrin. By contrast, fecal microbiota transplantation or interleukin-17A neutralization prevented ABX-induced immunosuppression. In independent lung, kidney, and bladder cancer patient cohorts, low serum levels of soluble MAdCAM-1 had a negative prognostic impact. Thus, the MAdCAM-1–α4β7 axis constitutes an actionable gut immune checkpoint in cancer immunosurveillance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intestinal dysbiosis, broadly defined as an imbalance in the composition or function of the gut microbiota, is a significant contributor to resistance against immune checkpoint inhibitor (ICI) therapies.1–16,”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [4]
In the citing paper
“Antibiotics predictably inflict the most acute damage, reducing diversity, depleting beneficial commensals, and permitting blooms of pathobionts like Enterocloster and Streptococcus.4,27,98”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [4]
In the citing paper
“For instance, our lab has shown that antibiotic-induced dysbiosis spurs the downregulation of mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1; discussed below) via altered BA metabolism (Fig. 3h).4”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [4]
In the citing paper
“Our lab recently reported that low baseline sMAdCAM-1 levels are strongly associated with gut dysbiosis in cancer patients.4,24”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [4]
In the citing paper
“This, in turn, allows immunosuppressive gut-resident α4β7+FoxP3+ regulatory Th17 (Tr17) cells to exit the gut and migrate to peripheral tumors, where they can blunt local antitumor immunity.4”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [4]
26 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationQuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“I mmune checkpoint inhibitors (ICIs) targeting the immunosuppressive interaction between programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) are used in the clinical management of many cancer types (1, 2).”
MethodGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 3×
“Moreover, FMT from some human donors fails to improve ICI responses (7, 35).”
BackgroundMethodSelf-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 2×
“I mmune checkpoint inhibitors (ICIs) targeting the immunosuppressive interaction between programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) are used in the clinical management of many cancer types (1, 2).”
BackgroundMethodVedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“, A novel endothelial L-selectin ligand activity in lymph node medulla that is regulated by alpha(1,3)fucosyltransferase-IV.”
BackgroundMultivariable association discovery in population-scale meta-omics studies
Mallick, H., Rahnavard, A., McIver, L. J., Ma, S., Zhang, Y., Nguyen, L. H., Tickle, T. L., Weingart, G., Ren, B., Schwager, E. H., et al. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009442 · Cited by 2,596
Cited by
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Self-citationRole of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 167
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M., & Galluzzi, L. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 123
Self-citationThe gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 119
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 144
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 124
Self-citationPhelps, C. M., Willis, N. B., Duan, T., Lee, A. H., Zhang, Y., Rodriguez J, D. M., Pandey, S. P., Laughlin, C. R., Rosen, A. B. I., McPherson, A. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.018 · Cited by 91
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationElkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 108
Self-citationThe future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 86
The gut microbiome and cancer response to immune checkpoint inhibitors
Gazzaniga, F. S., & Kasper, D. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184321 · Cited by 92
A dynamic atlas of immunocyte migration from the gut
Galván-Peña, S., Zhu, Y., Hanna, B. S., Mathis, D., & Benoist, C. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi0672 · Cited by 74
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00630-w · Cited by 68
“Patients who did not receive antibiotic had enrichment of speci fi cally Ruminococcaceae UCG 13, Clos-tridiales, and Agathobacter , whereas patients with antibiotic exposure had enrichment of Hungatella 11 , also associatedwith shorterOS inpatients with NSCLCtreatedwithIO 12 .”
InfluentialSelf-citationChen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Self-citationGeng, S., Guo, P., Li, X., Shi, Y., Wang, J., Cao, M., Zhang, Y., Zhang, K., Li, A., Song, H., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12687 · Cited by 68
The Microbiome and Cancer: A Translational Science Review
Fernandez, E., Wargo, J. A., & Helmink, B. A. (2025) · JAMA · doi:10.1001/jama.2025.2191 · Cited by 95
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Self-citationPorcari, S., Ng, S. C., Zitvogel, L., Sokol, H., Weersma, R. K., Elinav, E., Gasbarrini, A., Cammarota, G., Tilg, H., & Ianiro, G. (2025) · Cell · doi:10.1016/j.cell.2025.04.016 · Cited by 61
Self-citationMicrobiota-derived metabolites: Key modulators of cancer immunotherapies
Perl, M., Fante, M. A., Herfeld, K., Scherer, J. N., Poeck, H., & Orberg, E. T. (2025) · Med · doi:10.1016/j.medj.2025.100773 · Cited by 66
Xia, L., Zhu, X., Wang, Y., & Lü, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217123 · Cited by 56
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 54
Metabolites as agents and targets for cancer immunotherapy
Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 66
Self-citationRole of the gut microbiota in tumorigenesis and treatment
Liu, Q., Yang, Y., Pan, M., Yang, F., Yu, Y., & Qian, Z. (2024) · Theranostics · doi:10.7150/thno.91700 · Cited by 47
Gut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
Gut Microbiota Modulation through Akkermansia spp . Supplementation Increases CAR T-cell Potency
Marcos-Kovandzic, L., Avagliano, M., Khelil, M. B., Srikanthan, J., Abdallah, R., Petrocelli, V., Rengassamy, J., Alfaro, A., Bied, M., Fidelle, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1230 · Cited by 45
Self-citationPharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 41
Microbiota-mediated mechanisms of mucosal immunity across the lifespan
Iliev, I. D., Blander, J. M., Collins, N., Guo, C., Longman, R., Sonnenberg, G. F., Zeng, M. Y., & Artis, D. (2025) · Nature Immunology · doi:10.1038/s41590-025-02281-w · Cited by 66
Guillot, N., Roméo, B., Manesh, S. S., Milano, G., Brest, P., Zitvogel, L., Hofman, P., & Mograbi, B. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.004 · Cited by 36
Self-citationLu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 45
Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity
Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Mikhalev, A. I., Midiber, K. Y., Pechnikova, V. V., & Biryukov, A. E. (2024) · Cells · doi:10.3390/cells13171437 · Cited by 37
Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45357-1 · Cited by 33
“Dysbiosis can modulate biliary salt composition, leading to a downregulation of MAdCAM-1 and the exodus of immunosuppressive enterotropic T cells promoting tumor growth 73 .”
Self-citationMS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Lee, P.-J., Hung, C.-M., Yang, A.-J., Hou, C.-Y., Chou, H.-W., Chang, Y.-C., Chu, W.-C., Huang, W.-Y., Kuo, W.-C., Yang, C.-C., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2380061 · Cited by 33
“8 Taken together, these studies indicated that the gut microbiota plays a vital role in regulating immune checkpoint marker expression and associated treatment efficacy.”
BackgroundMechanisms and functions of intestinal vascular specialization
Bernier‐Latmani, J., González‐Loyola, A., & Petrova, T. V. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20222008 · Cited by 41
Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer
Lee, W. S., Lee, S. J., Lee, H. J., Yang, H., Go, E., Enkhtaivan, G., Song, K., Xiang, X., Park, D.-G., Alain, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53347-6 · Cited by 36
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Self-citationTumor-resident microbes: the new kids on the microenvironment block
Li, L., Chandra, V., & McAllister, F. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2023.12.002 · Cited by 30
Xin, Y., Liu, C., Zang, D., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343450 · Cited by 39
Self-citationGut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 33
del Socorro, T. P., Oka, K., Boulard, O., Takahashi, M., Poulin, L. F., Hayashi, A., & Chamaillard, M. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2315631 · Cited by 32
Laurans, L., Mouttoulingam, N., Chajadine, M., Lavelle, A., Diedisheim, M., Bacquer, E., Creusot, L., Suffee, N., Esposito, B., Melhem, N. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113350 · Cited by 34
Self-citationIntratumoral Microbiome: Foe or Friend in Reshaping the Tumor Microenvironment Landscape?
Kyriazi, A. A., Karaglani, M., Agelaki, S., & Baritaki, S. (2024) · Cells · doi:10.3390/cells13151279 · Cited by 33
Duttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023) · Current Oncology · doi:10.3390/curroncol30110681 · Cited by 31
Self-citationSaid, S., & Ibrahim, W. (2025) · Cancer Management and Research · doi:10.2147/cmar.s405590 · Cited by 25
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citationMessaoudene, M., Ferreira, S., Saint-Lu, N., Ponce, M., Truntzer, C., Boidot, R., Le Bescop, C., Loppinet, T., Corbel, T., Féger, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52373-8 · Cited by 24
Self-citationSucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Morder, K. M., Nguyen, M., Wilfahrt, D. N., Dahmani, Z. L., Burr, A. B. P., Xie, B., Morikone, M., Nieves-Rosado, H. M., Gunn, W. G., Hurd, D. E., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0247 · Cited by 30
Abbondio, M., Tanca, A., Diego, L. D., Sau, R., Bibbò, S., Pes, G. M., Dore, M. P., & Uzzau, S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2291170 · Cited by 25
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
Self-citationNew insights into gut microbiota–prostate cancer crosstalk
Laaraj, J., Lachance, G., Bergeron, A., Fradet, Y., Robitaille, K., & Fradet, V. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.015 · Cited by 27
Gut Microbiota–Related Biomarkers in Immuno-Oncology
Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061124-102218 · Cited by 22
Self-citationMicrobiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives
Li, D., Wu, R., Yu, Q., Tuo, Z., Wang, J., Yoo, K. H., Wei, W., Yang, Y., Ye, L., Guo, Y., et al. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.06.03 · Cited by 30
MAIT cell homing in intestinal homeostasis and inflammation
Wu, Z., Chen, X., Han, F., & Leeansyah, E. (2025) · Science Advances · doi:10.1126/sciadv.adu4172 · Cited by 23
Wekking, D., Silva, C. A. C., Viscò, R., Denaro, N., Lambertini, M., Maccioni, A., Loddo, E., Willard-Gallo, K. E., Scartozzi, M., Derosa, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104767 · Cited by 30
Self-citationThe missing hallmark of health: psychosocial adaptation
López-Otín, C., & Kroemer, G. (2024) · Cell Stress · doi:10.15698/cst2024.03.294 · Cited by 32
Self-citationAdvanced Bioinspired Multifunctional Platforms Focusing on Gut Microbiota Regulation
Li, M., Wang, L., Lin, D., Liu, Z., Wang, H., Yang, Y., Sun, C., Ye, J., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c05013 · Cited by 28
Zhao, S., Lu, Z., Zhao, F., Tang, S., Zhang, L., & Feng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1538969 · Cited by 32
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers
Birebent, R., Drubay, D., Alves Costa Silva, C., Marmorino, F., Vitali, G., Piccinno, G., Hurtado, Y., Bonato, A., Belluomini, L., Messaoudene, M., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2484880 · Cited by 21
“54 The shedding of MAdCAM-1, first described 20 years ago, occurs in the gut lymphoid tissues but also in the liver (in humans but not in mice).”
InfluentialSelf-citationLin, D., Chen, X., Lin, X., Zhang, C., Liang, T., Zheng, L., Xu, Y., Huang, L., Qiao, Q., & Xiong, K. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138308 · Cited by 23
Role of gut microbiome in suppression of cancers
Xu, Y., Gao, Z., Liu, J., Yang, Q., & Xu, S. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2495183 · Cited by 21
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Self-citationGut microbiome in IBD: past, present and the future
Zhang, J., Mak, J. W. Y., & Ng, S. C. (2025) · Gut · doi:10.1136/gutjnl-2025-335626 · Cited by 28
Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors
Wang, Q., Chen, Z., Zhang, G., Yang, J., Hu, R., Yao, T., Zeng, C., Zhang, S., Jiang, W., Zhu, S., et al. (2026) · Science · doi:10.1126/science.adu7686 · Cited by 23
Bifidobacterium in anticancer immunochemotherapy: friend or foe?
Procaccianti, G., Roggiani, S., Conti, G., Brigidi, P., Turroni, S., & D’Amico, F. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.23 · Cited by 29
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu, X.-L., Li, S., Ma, K.-X., & Wang, L. (2024) · Biochimica et Biophysica Acta - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167230 · Cited by 20
He, J. Y., Kim, Y.-J., Mennillo, E., Rusu, I., Bain, J. L., Rao, A. A., Andersen, C., Law, K., Yang, H., Tsui, J. L., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008628 · Cited by 25
Li, Z., Deng, L., Cheng, M., Ye, X., Yang, N., Fan, Z., & Sun, L. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5730 · Cited by 22
Li, L., Wu, J., Lin, Y., Chen, S., Li, M., Liu, X., Hou, J., & Zhou, S. (2025) · ACS Nano · doi:10.1021/acsnano.5c10295 · Cited by 19
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Shang, J., Valle, D. M. D., Britton, G. J., Mead, K., Rajpal, U., Chen-Liaw, A., Mogno, I., Li, Z., Menon, R., Gonzalez‐Kozlova, E., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232079 · Cited by 17
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance
Zhang, P., Chen, K., Liu, W., Niu, X., Wang, X., Wang, J., Yao, W., Tang, X., & Tian, W. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1608480 · Cited by 24
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy
Jani, C., Edwards, K., Bhanushali, C. D., Zheng, X. X., Salazar, A. S., Lopes, G. D. L., Jr., & Watson, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713382 · Cited by 21
Luo, W., Mei, S., Huang, Z., Chen, Z., Zhang, Y., Yang, M., Liu, J., Xu, J., Yang, X., Zhong, R.-W., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05135-5 · Cited by 25
Impact of the Lung Microbiota on Development and Progression of Lung Cancer
Belaïd, A., Roméo, B., Rignol, G., Benzaquen, J., Audoin, T., Vouret‐Craviari, V., Brest, P., Varraso, R., von Bergen�, M., Marquette, C., et al. (2024) · Cancers · doi:10.3390/cancers16193342 · Cited by 18
Diop, K., Mbaye, B., Nili, S., Filin, A., Benlaïfaoui, M., Malo, J., Renaud, A. S., Belkaïd, W., Hunter, S., Messaoudene, M., et al. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00694-4 · Cited by 17
Self-citationGut microbiota — bidirectional modulator: role in inflammatory bowel disease and colorectal cancer
Cui, X., Li, C., Zhong, J., Liu, Y., Xiao, P., Liu, C., Zhao, M., & Yang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1523584 · Cited by 17
Bredon, M., le Malicot, K., Louvet, C., Evesque, L., Gonzalez, D., Tougeron, D., & Sokol, H. (2025) · Gastroenterology · doi:10.1053/j.gastro.2024.10.020 · Cited by 14
The microbiota in radiotherapy-induced cancer immunosurveillance
Chen, J., Deutsch, É., Kroemer, G., Galluzzi, L., & Zitvogel, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01052-8 · Cited by 19
Self-citationThe multi-kingdom cancer microbiome
Dohlman, A. B., Pan, X., Zitvogel, L., & Iliev, I. D. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02103-7 · Cited by 18
Self-citationWang, X., Xu, T., Wu, S., Li, L., Cai, X., Chen, F., & Yan, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216814 · Cited by 16
The Link Between the Gut Microbiome and Bone Metastasis
Ševčíková, A., Martiniaková, M., Omelka, R., Števurková, V., & Čierniková, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212086 · Cited by 19
Yan, C., Chen, Y., Tian, Y., Hu, S., Wang, H., Zhang, X., Chu, Q., Huang, S., & Sun, W. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01103-3 · Cited by 14
Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Silva, C. A. C., Machaalani, M., Saliby, R. M., Zhong, C., Xie, W., Pasolli, E., Piccinno, G., Dalban, C., Fidelle, M., Meurisse, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04067-x · Cited by 17
Self-citationKoleva, P. T., He, J., Dunsmore, G., Bozorgmehr, N., Lu, J., Huynh, M., Tollenaar, S. L., Huang, V., Walter, J., Way, S. S., et al. (2024) · Microbiome · doi:10.1186/s40168-024-01859-0 · Cited by 16
Zhang, W., Zhang, H., Gao, Y., Lei, J., & Suo, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1596688 · Cited by 17
Bridging the Gap in Breast Cancer Dormancy: Models, Mechanisms, and Translational Challenges
Sabit, H., Abdel-Ghany, S. E., Albrahim, Y., Wadan, A.-H. S., Rashwan, S., Arneth, R., & Arneth, B. M. (2025) · Pharmaceuticals · doi:10.3390/ph18070961 · Cited by 16
Yin, Q., Ni, J., & Ying, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1263 · Cited by 13
Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance
Fidelle, M., Tian, A.-L., Zitvogel, L., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2224672 · Cited by 10
“Subsequent in vivo experiments confirmed that gavage with either LCA and UDCA is sufficient to trigger the reduction of Madcam1 mRNA expression in vivo, in the ileum, Peyer’s patches and mesenteric lymph nodes.(7) However, at this point, it remains to be clarified how these effects of LCA and UDCA are achieved at the…”
BackgroundResultInfluentialSelf-citationHost-microbiota interactions in genitourinary cancer immunotherapy
Xu, X., Cui, J., Li, W., Xu, Y., Yuan, S., Zeng, X., & Li, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.005 · Cited by 12
Oral Microbiome and CPT1A Function in Fatty Acid Metabolism in Oral Cancer
Kim, M. K., Praveen, Z., Choi, S., Lee, J. H., Park, J., Oh, H. J., Kwon, I. J., & Park, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010890 · Cited by 13
Immune cell infiltrates in peritoneal metastases from colorectal cancer
Sundström, P., Hogg, S., Quiding‐Järbrink, M., & Lindskog, E. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347900 · Cited by 9
The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage
L'Orphelin, J. ‐., Dompmartin, A., & Dréno, B. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13224 · Cited by 14
Cutting‐Edge Advancements in the Antibiotics‐Gut Microbiota‐Urinary Tumour Axis
Wang, J., Li, D., Wu, R., & Feng, D. (2025) · Cell Proliferation · doi:10.1111/cpr.70023 · Cited by 9
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy
Almonte, A. A., & Zitvogel, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011540 · Cited by 9
Self-citation
Metadata
- Authors
- Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., Pizzato, E., Birebent, R., Mbogning Fonkou, M. D., Zoppi, S., Reni, A., Dalban, C., Leduc, M., Ferrere, G., Durand, S., Ly, P., Silvin, A., Mulder, K., Dutertre, C.-A., Ginhoux, F., Yonekura, S., Roberti, M. P., Tidjani-Alou, M., Terrisse, S., Chen, J., Kepp, O., Schippers, A., Wagner, N., Suárez-Gosálvez, J., Kobold, S., Fahrner, J.-E., Richard, C., Bosq, J., Lordello, L., Vitali, G., Galleron, N., Quinquis, B., Le Chatelier, E., Blanchard, L., Girard, J.-P., Jarry, A., Gervois, N., Godefroy, E., Labarrière, N., Koschny, R., Daillère, R., Besse, B., Truntzer, C., Ghiringhelli, F., Coatnoan, N., Mhanna, V., Klatzmann, D., Drubay, D., Albiges, L., Thomas, A. M., Segata, N., Danlos, F.-X., Marabelle, A., Routy, B., Derosa, L., Kroemer, G., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- Gustave Roussy Cancer Campus, Villejuif Cedex, France.
- Centre Hospitalier de l’Université de Montréal (CA)
- University of Parma (IT)
- University of Verona (IT)
- Centre Léon Bérard (FR)
- Universitätsklinikum Aachen (DE)
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich, Germany.
- Center for Integrated Protein Science Munich (DE)
- JBO Consultant, Paris, France.
- Université Paris-Saclay (FR)
- MetaGenoPolis, INRAe, Université Paris-Saclay, Jouy en Josas, France.
- Centre National de la Recherche Scientifique (FR)
- University Hospital Heidelberg (DE)
- Institut Gustave Roussy (FR)
- University of Trento (IT)
- Corresponding author
- Fidelle, Marine
- Rauber, Conrad
- Derosa, Lisa
- Kroemer, Guido
- Zitvogel, Laurence
- ORCID
- Fidelle, Marine
- Rauber, Conrad
- Alves Costa Silva, Carolina
- Tian, Ai-Ling
- Zhao, Liwei
- Messaoudene, Meriem
- Birebent, Roxanne
- Mbogning Fonkou, Maxime Descartes
- Zoppi, Silvia
- Reni, Anna
- Dalban, Cécile
- Leduc, Marion
- Ferrere, Gladys
- Durand, Sylvère
- Ly, Pierre
- Silvin, Aymeric
- Mulder, Kevin
- Dutertre, Charles-Antoine
- Ginhoux, Florent
- Yonekura, Satoru
- Roberti, Maria Paula
- Tidjani-Alou, Maryam
- Terrisse, Safae
- Chen, Jianzhou
- Kepp, Oliver
- Schippers, Angela
- Wagner, Norbert
- Suárez-Gosálvez, Javier
- Kobold, Sebastian
- Fahrner, Jean-Eudes
- Richard, Corentin
- Bosq, Jacques
- Lordello, Leonardo
- Galleron, Nathalie
- Quinquis, Benoît
- Le Chatelier, Emmanuelle
- Blanchard, Lucas
- Girard, Jean-Philippe
- Jarry, Anne
- Gervois, Nadine
- Godefroy, Emmanuelle
- Labarrière, Nathalie
- Koschny, Ronald
- Daillère, Romain
- Besse, Benjamin
- Truntzer, Caroline
- Ghiringhelli, François
- Coatnoan, Nicolas
- Mhanna, Vanessa
- Klatzmann, David
- Drubay, Damien
- Albiges, Laurence
- Thomas, Andrew Maltez
- Segata, Nicola
- Danlos, François-Xavier
- Marabelle, Aurélien
- Routy, Bertrand
- Derosa, Lisa
- Kroemer, Guido
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2023-06-09
- Volume
- 380
- Issue
- 6649
- Pages
- eabo2296-eabo2296
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4379780265
- Cited by
- 243
- References
- 83
- Citations by year
- 2026: 74 · 2025: 86 · 2024: 58 · 2023: 25
- FWCI
- 29.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (publishedVersion)
- HAL (submittedVersion)
- HAL (submittedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche (ANR-16-RHUS-0001, ANR-21-ESRE-0028, ANR-18-IBHU-0002, ANR-19-CE15-0029, ANR-21-RHUS-0017, ANR-18-IDEX-0001)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- antibiotics, gut microbiota, MAdCAM-1, alpha4beta7 integrin, regulatory T cells, anti-PD-1 therapy, tumor immunosuppression, Enterocloster, fecal microbiota transplantation, IL-17A, prognostic factors, lung cancer, kidney cancer, bladder cancer
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Animals, Anti-Bacterial Agents, Bacteria, Cell Movement, Humans, Immune Tolerance, Immunologic Surveillance, Mucoproteins, Neoplasms, Cell Adhesion Molecules, Integrins, Drug Resistance, Neoplasm, Interleukin-17, Gastrointestinal Tract, Mice, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.